A Phase 2 interventional study of eteplirsen in Duchenne Muscular Dystrophy (DMD), sponsored by Sarepta Therapeutics, Inc.. Completed at 13 sites in United States. Open to male participants aged 4 Years to 6 Years. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 7 in phase 2, and was the 7th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 6 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 1 started in 2015.
This study's enrollment of 33 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 12th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2015, is one of 7 in phase 2, and was the 7th registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.
Clinical efficacy, including functional tests and MRI, will be assessed at regularly scheduled study visits. Patients will undergo one baseline and one follow-up muscle biopsy.
Population and serial PK will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
Drug: eteplirsen
Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
Also known as: AVI-4658, EXONDYS 51®
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
Adverse Event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug \[up to 100 weeks\]) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
Time frame: Baseline up to 100 weeks
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEs
Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
Time frame: Baseline up to 100 weeks
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
Time frame: Baseline up to 100 weeks
Number of Participants With at Least One Abnormal Physical Examination Finding
Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Number of participants with at least one abnormal physical examination findings were reported. Abnormality in physical examinations was based on Investigator's discretion.
Time frame: Baseline up to 100 weeks
Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEs
Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECGs were reported as TEAEs.
Time frame: Baseline up to 96 weeks
Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEs
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECHO were reported as TEAEs.
Time frame: Baseline up to 96 weeks
Change From Baseline in Dystrophin Protein Levels Quantified by Western Blot at Week 48 and 96
Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Week 48 and 96 was reported. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.
Time frame: Baseline, Week 48 and 96
Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 and 96
Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry at Week 48 and 96 was reported.
Time frame: Baseline, Week 48 and 96
The study was conducted at 13 sites in the United States.
| Milestone | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| Started | 26 | 7 |
| Completed | 25 | 3 |
| Not completed | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Unable to complete due to schooling | 0 | 1 |
| Withdrew: Transitioned to commercial drug | 1 | 0 |
Adverse Event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug \[up to 100 weeks\]) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
| Participants | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| Participants with TEAEs | 26 | 5 |
| Participants with Serious TEAEs | 4 | 0 |
| Participants with TEAEs leading to discontinuation | 0 | 0 |
Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
| Participants | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| SC: Blood creatine phosphokinase increased | 1 | 0 |
| Hematology: Anaemia | 1 | 0 |
| Hematology: Iron deficiency Anaemia | 1 | 0 |
| Urinalysis: chromaturia | 3 | 0 |
| Urinalysis: pollakiuria | 1 | 0 |
| Coagulation: Thrombocytopenia | 0 | 0 |
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.
| Participants | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| Pyrexia | 11 | 1 |
| Pulse pressure increased | 1 | 0 |
| Tachycardia | 1 | 0 |
Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Number of participants with at least one abnormal physical examination findings were reported. Abnormality in physical examinations was based on Investigator's discretion.
| Participants | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| Number of Participants With at Least One Abnormal Physical Examination Finding | 23 | 4 |
Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECGs were reported as TEAEs.
| Participants | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEs | 1 | 0 |
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECHO were reported as TEAEs.
| Participants | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEs | 1 | 0 |
Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Week 48 and 96 was reported. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.
| Percent Normal Dystrophin Protein Level | Eteplirsen 30 mg/kg |
|---|---|
| Change at Week 48 | 0.102 ± 0.0896 |
| Change at Week 96 | 0.321 ± 0.4863 |
Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry at Week 48 and 96 was reported.
| Percent dystrophin positive fibers | Eteplirsen 30 mg/kg |
|---|---|
| Change at Week 48 | 0.004 ± 0.0096 |
| Change at Week 96 | 0.015 ± 0.0175 |
Collected over Baseline up to 100 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eteplirsen 30 mg/kg | 0/26 (0%) | 4/26 (15.4%) | 26/26 (100%) |
| Control Group (Untreated) (Non-exon 51 Amenable Participants) | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Event | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| Foreign bodyInjury, poisoning and procedural complications | 1/26 | 0/7 |
| Coxsackie viral infectionInfections and infestations | 1/26 | 0/7 |
| InfluenzaInfections and infestations | 1/26 | 0/7 |
| Rhinovirus infectionInfections and infestations | 1/26 | 0/7 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/26 | 0/7 |
| Event | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 23/26 | 3/7 |
| NasopharyngitisInfections and infestations | 16/26 | 2/7 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 13/26 | 0/7 |
| RashSkin and subcutaneous tissue disorders | 13/26 | 0/7 |
| Upper respiratory tract infectionInfections and infestations | 11/26 | 1/7 |
| VomitingGastrointestinal disorders | 11/26 | 2/7 |
| PyrexiaGeneral disorders | 11/26 | 1/7 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 10/26 | 0/7 |
| HeadacheNervous system disorders | 10/26 | 0/7 |
| FallInjury, poisoning and procedural complications | 9/26 | 0/7 |
Full set included all participants who were enrolled in the eteplirsen group and received at least 1 dose of eteplirsen as well as all participants who were enrolled in the untreated group and had at least 1 assessment post-enrollment assessment.
| Age, Continuous(years) | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| Mean | 5.0 ± 0.82 | 5.0 ± 1.00 | 5.0 ± 0.85 |
| Sex: Female, Male(Participants) | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 26 | 7 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 0 | 5 |
| Not Hispanic or Latino | 21 | 7 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 22 | 6 | 28 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Eteplirsen 30 mg/kg | Control Group (Untreated) (Non-exon 51 Amenable Participants) | Total |
|---|---|---|---|
| United States | 26 | 7 | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Dec 2018, 41 months.
Results were first posted in Jul 2020, 1 year 7 months after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 41 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →